GENETIC mutationNUCLEOTIDE sequencingCOMBINATION drug therapyCLINICAL trialsNext-generation sequencing of samples from patients with acute myeloid leukemia (AML) has revealed several driver gene mutations in adult AML. However, unlike other cancers, AML is defined by relatively few mutation...
Patients with AML average 5 recurrent gene mutations. Patients with mutations in NPM1, or in CEBPA have a more favorable prognosis. Mutations in FLT3, on the other hand, have a poorer prognosis (including in patients who also have an otherwise favorable NPM1 mutation). ...
DOX的原发性与继发性耐药产生的分子机制有许多种,目前尚无定论,耐药性分子机制涉及多耐药基因-1(multidrugresistancegene1,MDR-1)编码的P-糖蛋白(P-gp)的过度表达、NF-kB、PI3K/Akt、STAT3、JNK等信号通路[9,10,,1,12,13,14]。在人类基因组测序计划陆续完成后,生命科学进入一个前所未有的新时代,在人类...
but not in a mammalian cell mutation assay (mouse lymphoma thymidine kinase) or transgenic rodent gene mutation assay with Big Blue rats [54]. Within the embryo-fetal toxicity studies of quizartinib in rats, there was no maternal toxicity and no evidence...
Notably, bromodomain and extra-terminal domain (BET) inhibitors, targeting the key component of super enhancers, the bromodomain containing protein (BRD) family, have shown potent anti-cancer effects in early clinical trials in AML patients.13 In addition, super enhancers have also been shown to ...
of all adult leukemias worldwide. Approximately one-third of AML patients have a FLT3 gene mutation. Such mutation can result in faster disease progression, higher relapse rates and lower rates of survival than other forms of AML. Inhibition of FLT3 mutation is of high importance in combating ...
https://bit.ly/2T1Sxmx A study of SNDX-5613 in R/R leukemias including those with an MLLr/KMT2A gene rearrangement or NPM1 Mutation (AUGMENT-101). Clinical Trials.gov. Updated November 6, 2020. Accessed December 3, 2020. https://www.clinicaltrials.gov/ct2/show/NCT04065399...
and the inclusion of additional gene mutations (RUNX1,ASXL1, andTP53) defining high risk. A new provisional response category, “progressive disease,” was also added, particularly for use in clinical trials. The response category “stable disease,” with the period of stable disease considered ...
BeatAML database included the clinical/cytogenetic/mutation/expression data originated from 672 patients. The WGCNA was used to identify the co-expression modules based on the scale-free network, and calculate the first principal component of gene modules as module eigengenes (MEs) [5, 6]. Then...
Several novel therapies targeting NPM1 are being developed in various clinical phases with demonstration of efficacy. In this review, we summarize the pathophysiology of the NPM1 gene mutation in AML, clinical implications and the novel targeted therapies to date. 0 被引用 · 0 笔记 引用 ...